STOCKHOLM, SWEDEN, - April 29, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new study published this week in Germany demonstrated  the clinical benefits of Nevisense in day-to-day practice. The study titled - "Electrical Impedance Spectroscopy Improves Skin Cancer Detection and Reduces the Number of Biopsies" and authored by Dr Liebich et al was published online in the journal Dermato.

SciBase hereby announces that the Annual report for 2021 is available at the Company's website www.scibase.com.

STOCKHOLM, SWEDEN, — March 30, 2022 – SciBase Holding AB (“SciBase”) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that its patent application : EP Application No. 18729063.0 has been granted by EPO in Europe. This patent is linked to the new measurement procedure instituted recently with the introduction of Nevisense 3.0.
 

STOCKHOLM, SWEDEN, - March 23, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today its inclusion in the launch of a multidisciplinary research consortium focused on six different dermatological disorders. The Next Generation Immunodermatology (NGID) consortium is based in the Netherlands and will run over 6 years, leveraging the expertise from several different groups across academic, clinical, and industrial research settings. The consortium has received funding of 11.7m euros to stimulate and support innovative approaches to identify and develop novel diagnostic and therapeutic approaches within dermatology.

STOCKHOLM, SWEDEN, - March 23, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders,  announced today that it has received its single largest order to date from a single clinic. The order for nearly 2,000 electrodes was received from an existing customer, a private Dermatology clinic in Germany. The order was valued at around 60k€ and will be delivered in April. The company has seen a significant increase in order volume following the announcement of an 8% increase in electrode prices from April 1.

2022-02-23 08:00 January 1 – December 31, 2021 The fourth quarter in figures Net sales amounted to TSEK 3,925 (3,055). The loss after tax amounted to TSEK 13,852 (9,839). The loss per share amounted to SEK 0.20 (0.20). The cash flow from current operations was negative in the amount of TSEK 11,709 (10,290). The gross margin reached 52.8% (49.4%). […]